LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

5p breached ! what next ?

4.75p !

next level is 6.2p followed by 8p and 12p or alteast thats what I read from the charts

Cool! bring it on !

Big news, change in directorship, New director from rubicon group, with experience in mergers and aquisitions.

PXS mean business then...

with yerterdays selling i guess short timers and some profit takers are out so hope we can march ahead again. 8p fingers crossed

3.75p to buy following recent market fall, good level to buy now

Chat on iii board suggests that an announcement is due by the end of this month.

Also, tipped in "Shares" magazine this week:-

http://www.sharesmagazine.com/node/1227

SAS Rue la Boetie
Credit Agricole SA
Calyon SA
Credit Agricole Cheuvreux SA 15,000,000 3.74%

it's clear that there is not much interest here for this share. I guess when news eventually arrives there will be a rush of interest lol, good 17% rise today and expectations rather than fact. Too many people have bene very patient with this one but it will come good.

Hi Global Nomad - I've been watching this one, too, and was pleased to see the shift yesterday. I'm convinced that contracts for Fruitflow will flow eventually, so am holding on to my shares.

Large volume today.

Announcement believed to be imminent.

I'll believe it when I see it !

I'll continue to hold but it's very tedious waiting around for the "good news"

I've been hanging around for ages on this one, and in the end sold as I got bored. However, today's Press Roundup has this from The Times: "Word of a tie-up between Provexis and Coca-Cola".

I think it's time to buy some again, while it's still quiet out there.

Yes, this from the Times this am... it all sounds rather laboured and drawn out and is based on evaluations at this stage..but... it's better than nothing !

AIM-listed Provexis, the developer of functional foods, held steady at 4.125p, despite word of a tie-up with Coca-Cola. The company is expected to confirm that the Atlanta-based soft drinks giant is evaluating the potential use of Fruitflow, Provexiss patented tomato extract, which it claims helps to thin the blood. Unilever is currently assessing the use of Fruitflow in dairy products.

Thanks Skyhigh - I'd not seen the details. I'm sure we'll get there eventually - have bought some this morning but didn't have a lot of spare cash as it's tied up elsewhere, waiting for profits...

From "Shares" magazine today:-

Provexis bears fruit
PXS
Published date:Thursday, October 11, 2007
Last month we reported that Provexis (PXS:AIM) was in discussions with both Coca-Cola (KO:NYSE) and PepsiCo (PEP:NYSE) about the possibility of licensing its Fruitflow technology to the drinks makers (Shares 6 September). As we go to press we understand that an announcement is imminent, probably this week.

The groups technology is designed to reduce the risk of heart disease and it is already being used under licence by Unilver (ULVR). Acceptance by one of the US drinks giants will certainly act as a further fillip for the shares, which have already risen 14% in the last month to 4.1p. In the longer term the Fruitflow technology could have further applications such as lowering the chances of deep-vein thrombosis (DVT), which would again be a significant market.

Shares says: At last the patience of shareholder is being rewarded. JM

SPECULATIVE BUY

missed 'last months report' entirely, did anyone actually see it/read it?

no move on price today seems odd, given the Times report and this article......

outlook123 - 08 Sep 2007 17:18 - 31 of 41

Chat on iii board suggests that an announcement is due by the end of this month.

Also, tipped in "Shares" magazine this week:-

http://www.sharesmagazine.com/node/1227